Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Deferred Revenue: 2023-2024

Historic Current Deferred Revenue for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $117.2 million.

  • Monte Rosa Therapeutics' Current Deferred Revenue rose 345.67% to $111.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.9 million, marking a year-over-year increase of 345.67%. This contributed to the annual value of $117.2 million for FY2024, which is 262.69% up from last year.
  • As of FY2024, Monte Rosa Therapeutics' Current Deferred Revenue stood at $117.2 million, which was up 262.69% from $32.3 million recorded in FY2023.
  • Over the past 5 years, Monte Rosa Therapeutics' Current Deferred Revenue peaked at $117.2 million during FY2024, and registered a low of $32.3 million during FY2023.
  • Moreover, its 2-year median value for Current Deferred Revenue was $74.8 million (2023), whereas its average is $74.8 million.
  • Data for Monte Rosa Therapeutics' Current Deferred Revenue shows a peak YoY skyrocketed of 262.69% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Monte Rosa Therapeutics' Current Deferred Revenue stood at $32.3 million in 2023, then soared by 262.69% to $117.2 million in 2024.